T-like NK cell therapy for cancers with low MHC-I
Part of Cancer, Immune system & allergy clinical trials.
This early-stage trial tests a lab-made immune cell treatment (T-like NK cells) for advanced cancers that have low or missing MHC-I on their cells. Because the treatment aims to “re-activate” the immune system against these cancers, you may be eligible if your cancer matches this feature and you meet safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer that shows low or no MHC-I (a surface marker on cancer cells; low means it may be harder for the immune system to recognize).
- You are expected to live more than 12 weeks.
- Your heart, lungs, liver, and kidneys are healthy enough for treatment (labs/scans must be adequate).
- Your own immune cells are available (the trial needs your T cells for the treatment).
- You (or your guardian) can understand the study and sign an informed consent, and you receive a copy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
This Phase 1 study tests engineered immune cells (TILs/CAR-TILs) made from your tumor to treat advanced solid cancers that have not responded to standard treatments. It may help your immune system better recognize and attack the cancer, but it is mainly focused on safety and early results.
This study tests a combination of three drugs (sintilimab, pegaspargase, and selinexor) followed by radiation therapy for newly diagnosed extranodal NK/T-cell lymphoma, a rare type of blood cancer. The goal is to see if this combination can help control the cancer better than standard treatment alone.
This Phase 1/2 study tests an intravenous (IV) immune-cell therapy made from donors (allogeneic NK cells) to treat advanced solid tumors, relapsed/refractory non-Hodgkin lymphoma, or multiple myeloma. It may help by targeting cancer cells more directly, but early-phase trials mainly focus on safety and finding the right dosing.
This trial tests an investigational natural killer (NK) cell therapy for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if these immune cells can shrink tumors and are safe.
This early-stage trial tests a new type of immune cell therapy (NK cells boosted with a protein called IL-15) to treat solid cancers that have spread or come back after standard treatment. The goal is to see if this approach can help shrink tumors and improve survival.
Hear when a new Anti-cancer Cell Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.